As the scale of Pune’s Guillain-Barré Syndrome (GBS) outbreak grows, with the number of cases rising to 101, there is much curiosity around the prognosis and treatment of the rare condition. Speaking ...
Annexon, Inc. (NASDAQ:ANNX) on Tuesday presented data for its late-stage targeted therapy, tanruprubart (formerly ANX005), for Guillain-Barré Syndrome (GBS). GBS is a neuromuscular emergency affecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback